



Improve outcomes. Reduce costs.

with respiratory-focused pharmacy and pharmacotherapy management program

1 in 5 hospitalizations are due to COPD, driving \$49 billion in annual costs.

60% of costs can be avoided by preventing exacerbations.

Conversio Health's unique approach is proven to enhance **patient adherence, education, and satisfaction**, bringing together all parties to **successfully manage patient care**.



"I haven't been able to breathe this well in 6 years."

- ✓ **Improved medication adherence and outcomes**
- ✓ **\$1500 drug savings PMPY**
- ✓ **\$850 average reduction in hospitalization cost PMPY**
- ✓ **85 Net Promoter Score vs. 28 for retail pharmacies**



Problems with treating COPD

Incorrect Inhaler Use

Research indicates that up to 85% of patients use their inhalers for COPD ineffectively¹

Medication Availability

Nebulized medication is recommended for children & the elderly, but most long-acting medications are only available in inhaler form

High Copays

94% of patients with income under \$25,000 do not fill prescriptions due to copays²

33% Adherence to Inhaled Therapy³

Average COPD hospitalization costs \$19,000⁴

Suboptimal Prescribing Patterns

55% of PCPs are unaware of WHO COPD Gold Standard prescribing guidelines⁵

Conversio Health Solutions

Pharmacotherapy Management

Clinical pharmacists provide recurring education to improve adherence & prevent exacerbations

Compounded Nebulized Medications

Conversio makes long-acting nebulized medications that eliminate issues with hand-breath coordination & low inspiratory flow

No Fee & Free Delivery

Compounded medications priced to offer meaningful patient & health plan savings

75% Average Medication Adherence

Naturally results in reduced hospitalizations

Clinical Monitoring Program

Conversio identifies suboptimal therapy & coordinates with MD to modify treatment as patient condition progresses

No PMPM fee
to patient, provider, or health plan

1 <https://www.pharmacist.com/focus-copd>
2 <https://healthitanalytics.com/news/cost-is-a-primary-driver-of-medication-non-adherence-rates>
3 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194635/>
4 https://app.cms.gov/docs/cost_specifications/2019-12-17-mif-ebcm-ip-copd.pdf
5 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629978/>